BMU Report Raises Alarm
Last-Resort Antibiotics Losing Their Power
- Meropenem resistance has reached 36.2% among major Gram-negative bacteria
- Resistance exceeds 95% in ICU respiratory samples for some pathogens
- MRSA prevalence has risen to 26.3% in the latest report
Drug-resistant bacteria are increasingly undermining the effectiveness of antibiotics in Bangladesh. Even meropenem, a powerful antibiotic used to treat severe hospital infections, is failing against more than one-third of major Gram-negative bacteria. The alarming findings are included in the Antimicrobial Resistance Report: 2025–2026, published by the Department of Microbiology and Immunology at Bangladesh Medical University (BMU). The report shows that carbapenem resistance among Klebsiella and Acinetobacter in respiratory samples from intensive care unit (ICU) patients has exceeded 95 per cent. This is making the treatment of serious infections increasingly difficult.
BMU has called for greater public awareness to address antimicrobial resistance (AMR). The university organised a public awareness rally and gathering on Wednesday (18 November) to mark Antimicrobial Awareness Week 2026. The programme was arranged by its Department of Microbiology and Immunology. Speakers warned that the indiscriminate and inappropriate use of antibiotics is allowing drug-resistant bacteria to spread in the human body. As a result, even antibiotics considered a last resort are failing in many cases.
This year's theme was “One Health, One Action: Prevent AMR Now”. The rally began in front of the university's B Block. BMU Vice-Chancellor Professor Dr FM Siddiqui inaugurated the programme as the chief guest.
Addressing the event, the vice-chancellor said access to antibiotics without a doctor's prescription must be stopped. He warned that indiscriminate antibiotic use had pushed antimicrobial resistance to a critical level. Consequently, when patients become ill and need antibiotics for treatment, the medicines often no longer work. He stressed that public awareness is essential to address the situation.
BMU Pro-Vice-Chancellor for Research and Development Professor Dr Md Mujibur Rahman Howlader spoke as the special guest. He said antibiotics have specific doses and treatment durations. Once a patient starts an antibiotic, it must be taken for the period prescribed by the doctor. Some antibiotics are also unsuitable in certain situations. He cited pregnancy as an example, noting that some antibiotics may harm an unborn child. He called for an end to the sale of antibiotics without medical advice.
Professor Dr Abu Naser Ibn Sattar, chairman of the Department of Microbiology and Immunology, chaired the programme. He said the misuse and careless use of antibiotics had made bacteria increasingly resistant to treatment. This has led to antimicrobial resistance in the human body, reduced the effectiveness of antibiotics and created a growing crisis in infection treatment.
Among those attending were BMU Registrar Professor Dr Md Mostafa Kamal; Dean of the Faculty of Dentistry Professor Dr Sakhawat Hossain Sayanth; Associate Professors Dr Shaheda Anwar, Dr Sanjida Khandaker Setu and Dr Ismet Nigar; Assistant Professor Dr SM Ali Ahmed; Pharmacology Department Chairman Professor Dr Jannatul Ferdous; and Associate Professor Dr Fatema Zohra. Teachers, doctors and resident physicians from different departments also took part.
Key Findings of the BMU Report
Professor Dr Abu Naser Ibn Sattar said the university's annual antimicrobial resistance report showed that carbapenem resistance had increased from 28.2 per cent to 36.2 per cent in one year. The rate exceeded 95 per cent in respiratory samples from ICU patients.
The report is based on samples collected from patients at the university's outpatient and inpatient departments between July 2025 and June 2026. Published in November 2026, it presents trends in antibiotic resistance among different pathogens.
Clinical sample analysis: During the reporting period, the Department of Microbiology and Immunology tested 50,844 clinical samples. This was higher than the 31,686 samples tested in 2011 and 46,279 in 2014–15. Bacteria were detected in 13,251 samples. One section of the report gives the rate as 29.1 per cent, while its summary lists 26.1 per cent.
Pathogens were detected in 37.6 per cent of 17,108 urine samples and 8 per cent of 16,104 blood samples. Nearly half of the identified pathogens came from urine samples. Wound, blood and sputum samples accounted for much of the remainder. E. coli was the most common organism in urine samples, accounting for 50.6 per cent, while Klebsiella accounted for 18.6 per cent of blood isolates. Pseudomonas was prominent in wound samples, while Klebsiella was common in sputum samples.
Carbapenem resistance: One of the report's most concerning findings is the declining effectiveness of carbapenem antibiotics. Among 10,536 samples of six major Gram-negative bacteria, 3,810 showed resistance to meropenem. This represents a resistance rate of 36.2 per cent, up from 28.2 per cent in the previous year.
Carbapenem resistance in Klebsiella increased from 27.6 per cent to 40 per cent in one year. In E. coli, it rose from 14 per cent to 20.7 per cent. Resistance was detected in 57.5 per cent of Acinetobacter and 52.1 per cent of Pseudomonas isolates. Although the rates for these two organisms declined slightly from the previous year, they remain above 50 per cent. The number of carbapenem-resistant Pseudomonas samples increased from 276 in 2022–23 to 937 in the latest reporting period.
The situation is more severe in bloodstream infections. Meropenem was ineffective against 56 per cent of Klebsiella, 62.1 per cent of Acinetobacter and 33.3 per cent of E. coli isolates obtained from blood samples. Resistance among Klebsiella and Acinetobacter in respiratory samples collected from ICU patients exceeded 95 per cent.
The report said this pattern was consistent with the use of carbapenems as first-line drugs in inpatient wards and ICUs. However, colistin, considered a last-resort antibiotic, remained effective in most cases. Across all samples, colistin resistance was detected in 0.4 per cent of Klebsiella and 0.8 per cent of Acinetobacter. In blood samples, the rates were 3.6 per cent and 3.1 per cent, respectively, raising concerns about future treatment options.
Antibiotics failing against urinary infections: E. coli, a major cause of urinary tract infections, showed resistance to amoxicillin in 82.8 per cent of cases, ciprofloxacin in 75.5 per cent, ceftriaxone in 62.2 per cent and gentamicin in 52.9 per cent.
Resistance to nitrofurantoin, a commonly used drug for urinary tract infections, rose from 33.3 per cent to 50.1 per cent in one year. Meropenem resistance in urinary E. coli also increased from 12.5 per cent to 18.4 per cent. However, the report identified piperacillin-tazobactam, colistin and tigecycline as drugs that remain effective. One positive finding was that the rate of ESBL-producing E. coli in urine samples declined from 3.16 per cent to 2.7 per cent.
MRSA on the rise: The report recorded 12 vancomycin-resistant Staphylococcus aureus isolates and 13 vancomycin-resistant Enterococcus isolates in urine samples. It also identified 13 linezolid-resistant Staphylococcus aureus isolates in urine.
Methicillin-resistant Staphylococcus aureus (MRSA) is also showing a steady increase. The MRSA rate in pus, wound, nasal and ear samples rose from 9.7 per cent in 2022–23 to 19.2 per cent in 2024–25. It reached 26.3 per cent in the latest report.
Resistance to typhoid medicines: Of 141 typhoid isolates obtained from blood samples, half were resistant to ciprofloxacin. The rate was 40.3 per cent in the previous year. Resistance to nalidixic acid stood at 69.7 per cent. Five isolates also failed to respond to ceftriaxone, a key drug for typhoid treatment, compared with four in the previous year. However, resistance to co-trimoxazole and chloramphenicol remained relatively low at 12 per cent and 14.9 per cent, respectively. The report noted that these drugs could again be considered effective alternatives.
Fungal infections in blood samples: Yeast was detected in 76 of 6,591 blood samples. Candida albicans and Candida tropicalis accounted for 22 samples each, followed by 18 samples of Candida ciferrii. Resistance to fluconazole in this species reached 71.2 per cent, compared with 40 per cent in the previous year. Micafungin remained effective against all species.
Why Antimicrobial Resistance Is Increasing
The report describes antimicrobial resistance as a “silent pandemic”. It identifies unnecessary and inappropriate antibiotic use as a major cause. Other contributing factors include taking antibiotics without prescriptions, pressure from patients, self-medication, inadequate doses and the use of broad-spectrum antibiotics without proper diagnosis.
The report identifies hospitals as hotspots for drug-resistant pathogens. It also warns that resistant infections can spread to other areas within a short period when infected patients move between hospitals or communities.
Drug-resistant infections are making common conditions such as pneumonia, sepsis and tuberculosis more difficult, and sometimes impossible, to treat. They increase the risk of death, prolong hospital stays and create a need for expensive medicines with potentially serious side effects. This places additional financial pressure on families and the healthcare system. The success of cancer chemotherapy, organ transplantation, major surgery and ICU treatment is also at risk.
Limitations and Recommendations
The report acknowledges several limitations. Due to the absence of an effective hospital and laboratory information system, researchers could not distinguish whether samples came from outpatient departments, inpatient wards or emergency departments. Patients' previous antibiotic-use histories were also unavailable. These limitations may have resulted in resistance rates appearing higher than the actual levels. However, the report said data quality was maintained through the External Quality Assessment Scheme (EQAS), internal quality control and monthly data monitoring.
To address AMR, the report recommends developing institution-specific antibiotic policies based on antibiogram data, expanding surveillance, introducing antimicrobial stewardship programmes, strengthening infection prevention and control, and improving laboratory capacity. It also calls for responsible antibiotic use in human and animal healthcare and the development of a national action plan.
Other recommendations include restricting carbapenem use in ICUs, enforcing strict infection-control measures and confirming all vancomycin-, linezolid- and colistin-resistant organisms through molecular testing. The report also calls for stronger research into drug-resistant tuberculosis and bacterial and fungal diseases by 2030.
The report was coordinated, written and compiled by department chairman and professor Dr Abu Naser Ibn Sattar, Associate Professor Dr Sanjida Khandaker Setu and other faculty members and MD resident physicians. It states that the findings will serve as an important resource for policymakers, doctors and researchers.
Report at a glance: A total of 50,844 samples were tested, with 13,251 showing bacterial growth. Carbapenem resistance among major Gram-negative bacteria stood at 36.2 per cent. Resistance in ICU respiratory samples exceeded 95 per cent for some pathogens. MRSA prevalence reached 26.3 per cent. Ciprofloxacin resistance among typhoid isolates stood at 50 per cent, while nitrofurantoin resistance in urinary E. coli reached 50.1 per cent.
The findings underline the importance of using antibiotics only under medical supervision and following prescribed doses and treatment durations. They also highlight the need for coordinated action involving hospitals, doctors, patients, policymakers and the animal health sector to contain the spread of antimicrobial resistance.
//DBTech/SMIH/RESME/FOPTE//





